CRISPR Therapeutics
CRSP

股本结构

单位：万股
公告日期 2025-11-10 2025-11-10 2025-08-04 2025-08-04 2025-05-06 2025-05-06
证券总股本 9530.02 9387.28 9095.04 8837.64 8636.37 8636.09
普通股本 9530.02 9387.28 9095.04 8837.64 8636.37 8636.09
优先股 未披露 未披露 未披露 未披露 未披露 未披露
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2025-11-06 2025-09-30 2025-08-01 2025-06-30 2025-05-02 2025-03-31
注释：中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本（万股） 变动后优先股（万股） 变动原因 变动日期
2025-11-10 9530.02 未披露 定期报告 2025-11-06
2025-11-10 9387.28 未披露
更多>>
From June 30, 2025 to September 30, 2025 Issuance of common stock, net of issuance costs of $6.5 million Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.3 million Purchase of common stock under ESPP
2025-09-30
2025-08-04 9095.04 未披露 定期报告 2025-08-01
2025-08-04 8837.64 未披露
更多>>
From March 31, 2025 to June 30, 2025 Issuance of common stock, net of issuance costs of $0.7 million Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.1 million
2025-06-30
2025-05-06 8636.37 未披露 定期报告 2025-05-02
2025-04-16 8636.32 未披露 定期报告 2025-04-15
2025-05-06 8636.09 未披露
更多>>
From December 31, 2024 to March 31, 2025 Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.2 million Issuance of common stock, net of issuance costs of $0.1 million Purchase of common stock under ESPP
2025-03-31
2025-04-16 8618.81 未披露 定期报告 2025-03-15
2025-02-11 8577.45 未披露 定期报告 2025-02-07
2025-02-11 8574.20 未披露
更多>>
From December 31, 2023 to December 31, 2024 Issuance of common shares, net of issuance costs of $4.0 million Purchase of common stock under ESPP Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.8 million
2024-12-31
2024-11-05 8535.35 未披露 定期报告 2024-11-01
2024-11-05 8533.58 未披露
更多>>
From June 30, 2024 to September 30, 2024 Issuance of common stock Vesting of restricted shares Exercise of vested options Purchase of common stock under ESPP
2024-09-30
2024-08-05 8516.82 未披露 定期报告 2024-08-01
2024-08-05 8504.55 未披露
更多>>
From March 31, 2024 to June 30, 2024 Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.2 million
2024-06-30
2024-05-08 8491.81 未披露 定期报告 2024-05-03
2024-04-09 8488.31 未披露 定期报告 2024-04-08
2024-05-08 8483.76 未披露
更多>>
From December 31, 2023 to March 31, 2024 Purchase of common stock under ESPP Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.6 million Issuance of common stock, net of issuance costs of $3.8 million
2024-03-31
2024-04-09 8474.62 未披露 定期报告 2024-03-15
2024-02-13 8334.85 未披露
更多>>
Common stock offered 3,916,082 shares by the company
2024-02-27
2024-02-21 8027.60 未披露 定期报告 2024-02-16
2024-02-21 8004.44 未披露
更多>>
From December 31, 2022 to December 31, 2023 Issuance of common shares, net of issuance costs of $2.9 million Purchase of common stock under ESPP Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.5 million
2023-12-31
2023-11-06 7943.24 未披露 定期报告 2023-11-02
2023-11-06 7942.67 未披露
更多>>
From June 30, 2023 to September 30, 2023 Exercise of vested options Purchase of common stock under ESPP Vesting of restricted shares
2023-09-30
2023-08-07 7941.15 未披露 定期报告 2023-08-03
2023-08-07 7937.24 未披露
更多>>
From March 31, 2023 to June 30, 2023 Exercise of vested options, net of issuance costs of $0.3 million Vesting of restricted shares
2023-06-30
2023-05-08 7893.51 未披露 定期报告 2023-05-05
2023-04-26 7888.97 未披露 定期报告 2023-04-17
2023-05-08 7886.37 未披露
更多>>
From December 31, 2022 to March 31, 2023 Purchase of common stock under ESPP Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.2 million
2023-03-31
2023-02-21 7864.67 未披露 定期报告 2023-02-16
2023-02-21 7851.25 未披露
更多>>
From December 31, 2021 to December 31, 2022 Issuance of common shares Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.9 million Purchase of common stock under ESPP
2022-12-31
2022-11-01 7829.41 未披露 定期报告 2022-10-28
2022-11-01 7824.78 未披露
更多>>
From June 30, 2022 to September 30, 2022 Issuance of common shares Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.3 million Purchase of common stock under ESPP
2022-09-30
2022-08-08 7800.93 未披露 定期报告 2022-08-04
2022-08-08 7779.22 未披露
更多>>
From March 31, 2022 to June 30, 2022 Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.2 million
2022-06-30
2022-05-09 7745.71 未披露 定期报告 2022-05-05
2022-04-25 7740.37 未披露 定期报告 2022-04-18
2022-05-09 7738.64 未披露
更多>>
From December 31, 2021 to March 31, 2022 Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.2 million Purchase of common stock under ESPP
2022-03-31
2022-04-25 7720.50 未披露 定期报告 2022-03-15
2022-02-15 7706.76 未披露 定期报告 2022-02-11
2022-02-15 7699.01 未披露
更多>>
From December 31, 2020 to December 31, 2021 Issuance of common shares, net of issuance costs of $5.4 million Vesting of restricted shares Exercise of vested options, net of issuance costs of $2.6 million Purchase of common stock under ESPP
2021-12-31
2021-11-03 7652.70 未披露 定期报告 2021-11-01
2021-11-03 7646.32 未披露
更多>>
From June 30, 2021 to September 30, 2021 Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.4 million Purchase of common stock under ESPP
2021-09-30
2021-07-29 7620.12 未披露 定期报告 2021-07-27
2021-07-29 7607.85 未披露
更多>>
From March 31, 2021 to June 30, 2021 Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.4 million
2021-06-30
2021-04-27 7576.89 未披露 定期报告 2021-04-23
2021-04-28 7575.90 未披露 定期报告 2021-04-16
2021-04-27 7573.06 未披露
更多>>
from December 31, 2020 to March 31, 2021 Issuance of common shares, net of issuance costs of $5.4 million Vesting of restricted shares Exercise of vested options, net of issuance costs of $1.5 million Purchase of common stock under ESPP
2021-03-31
2021-04-28 7561.26 未披露 定期报告 2021-03-15
2021-02-16 7542.89 未披露 定期报告 2021-02-11
2021-02-16 7391.48 未披露
更多>>
From December 31, 2019 to December 31, 2020 Issuance of common shares, net of issuance costs of $46.4 million Vesting of restricted shares Exercise of vested options, net of issuance costs of $1.2 million Purchase of common stock under ESPP Issuance of common stock for license agreements
2020-12-31
2020-12-11 7120.71 未披露 定期报告 2020-11-30
2020-10-28 7065.24 未披露 定期报告 2020-10-23
2020-10-28 7060.39 未披露
更多>>
From June 30, 2020 to September 30, 2020 Issuance of common shares,net of issuance costs of $32.8 million Vesting of restricted shares Exercise of vested options Purchase of common stock under ESPP
2020-09-30
2020-07-27 7017.20 未披露 定期报告 2020-07-23
2020-07-06 6838.94 未披露
更多>>
1.Common shares offered by the company 6,428,572 shares 2.The number of common shares to be outstanding after the offering is based on 61,960,804 common shares outstanding as of June 15, 2020
2020-07-06
2020-07-27 6255.25 未披露
更多>>
From March 31, 2020 to June 30, 2020 Issuance of common shares, net of issuance costs of $3.1 million Vesting of restricted shares Exercise of vested options
2020-06-30
2020-06-29 6196.08 未披露 定期报告 2020-06-15
2020-04-28 6101.77 未披露 定期报告 2020-04-24
2020-04-24 6101.14 未披露 定期报告 2020-04-13
2020-04-28 6089.00 未披露
更多>>
From December 31, 2019 to March 31, 2020 Vesting of restricted shares Exercise of vested options Issuance of common shares related to license agreement
2020-03-31
2020-04-24 6088.82 未披露 定期报告 2020-03-15
2020-02-12 6084.57 未披露 定期报告 2020-02-07
2020-02-12 6078.38 未披露
更多>>
from December 31, 2018 to December 31, 2019 Issuance of common shares, net of issuance costs of $25.1 million Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.3 million
2019-12-31
2019-10-28 5520.42 未披露 定期报告 2019-10-24
2019-10-28 5518.94 未披露
更多>>
from June 30, 2019 to September 30, 2019 Issuance of common shares, net of issuance costs of $2.3 million Vesting of restricted shares Exercise of vested options
2019-09-30
2019-07-29 5466.25 未披露 定期报告 2019-07-25
2019-07-29 5349.91 未披露
更多>>
from March 31, 2019 to June 30,2019 Issuance of common shares, net of issuance costs of $1.3 million Vesting of restricted shares Exercise of vested options
2019-06-30
2019-04-29 5291.00 未披露 定期报告 2019-04-25
2019-04-30 5287.85 未披露 定期报告 2019-04-12
2019-04-29 5263.56 未披露
更多>>
from December 31, 2018 to March 31, 2019 Issuance of common stock, net of issuance costs of $1.2 million Vesting of restricted shares Exercise of vested options
2019-03-31
2019-02-25 5227.92 未披露 定期报告 2019-02-21
2019-02-25 5185.29 未披露
更多>>
from December 31, 2017 to December 31, 2018 Issuance of common stock, net of issuance costs of $23.8 million Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.4 million Repurchase of treasury shares Issuance of shares to ViaCyte
2018-12-31
2018-11-07 5189.70 未披露 定期报告 2018-11-01
2018-11-07 5155.45 未披露 定期报告 2018-09-30
2018-09-19 4719.29 未披露 定期报告 2018-09-01
2018-08-07 4758.69 未披露 定期报告 2018-08-01
2018-08-07 4707.18 未披露 定期报告 2018-06-30
2018-05-08 4718.68 未披露 定期报告 2018-04-30
2018-04-18 4716.69 未披露 定期报告 2018-04-02
2018-05-08 4668.08 未披露 定期报告 2018-03-31
2018-04-18 4706.99 未披露 定期报告 2018-03-15
2018-03-08 4697.60 未披露 定期报告 2018-02-28
2018-03-08 4059.22 未披露
更多>>
from December 31, 2016 to December 31, 2017 Vesting of restricted shares Exercise of vested options
2017-12-31
2017-11-08 4101.94 未披露 定期报告 2017-11-03
2017-11-09 4100.28 未披露 定期报告 2017-11-01
2017-11-08 4038.19 未披露 定期报告 2017-09-30
2017-08-10 4059.17 未披露 定期报告 2017-08-07
2017-08-10 4003.94 未披露 定期报告 2017-06-30
2017-05-11 3999.75 未披露 定期报告 2017-05-08
2017-04-18 4025.84 未披露 定期报告 2017-04-03
2017-03-10 3981.01 未披露 定期报告 2017-03-01
2017-03-10 3971.94 未披露
更多>>
from December 31, 2015 to December 31, 2016 Conversion of Convertible Loans Receipt of Series A-3 Subscription Receivable Issuance of Series B Preferred Shares, net of issuance costs of $1.8 million Conversion of redeemable convertible preferred shares into common share Adjustment to Noncontrolling interest upon share exchange for TRACR Issuance of common stock, net of issuance costs of $8.3 million Repurchase of treasury shares Vesting of restricted shares Exercise of vested options
2016-12-31
2016-11-22 3980.88 未披露 定期报告 2016-11-21
2016-10-19 3936.06 未披露
更多>>
The conversion of all 27,135,884 of our outstanding preferred shares into common shares on a one-for-one basis immediately prior to the closing of this offering; The issuance of 328,017 common shares to Dr. Emmanuelle Charpentier immediately prior to the closing of this offering pursuant to a call option agreement, dated March 20, 2015, between us and Dr. Emmanuelle Charpentier, or the Call Option Agreement; The filing and effectiveness of our amended articles of association and creation of authorized and conditional share capital of 31,724,612 common shares upon closing of this offering; The issuance and sale by us in the concurrent private placement of 2,500,000 common shares to Bayer BV; No exercise of the underwriters’ over-allotment option to purchase up to 600,000 additional common shares.
2016-10-19
2016-11-22 530.78 2713.59 定期报告 2016-09-30
2016-09-09 526.27 2713.59
更多>>
from December 31, 2015 to June 30, 2016 Repurchase of treasury shares Vesting of restricted shares Conversion of convertible loans into Series B preferred shares at $13.43 per share (unaudited) Receipt of Series A-3 Subscription Receivable Issuance of Series B Preferred Shares, net of issuance costs of $1.8 million
2016-06-30
From June 30, 2025 to September 30, 2025 Issuance of common stock, net of issuance costs of $6.5 million Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.3 million Purchase of common stock under ESPP
From March 31, 2025 to June 30, 2025 Issuance of common stock, net of issuance costs of $0.7 million Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.1 million
From December 31, 2024 to March 31, 2025 Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.2 million Issuance of common stock, net of issuance costs of $0.1 million Purchase of common stock under ESPP
From December 31, 2023 to December 31, 2024 Issuance of common shares, net of issuance costs of $4.0 million Purchase of common stock under ESPP Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.8 million
From June 30, 2024 to September 30, 2024 Issuance of common stock Vesting of restricted shares Exercise of vested options Purchase of common stock under ESPP
From March 31, 2024 to June 30, 2024 Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.2 million
From December 31, 2023 to March 31, 2024 Purchase of common stock under ESPP Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.6 million Issuance of common stock, net of issuance costs of $3.8 million
Common stock offered 3,916,082 shares by the company
From December 31, 2022 to December 31, 2023 Issuance of common shares, net of issuance costs of $2.9 million Purchase of common stock under ESPP Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.5 million
From June 30, 2023 to September 30, 2023 Exercise of vested options Purchase of common stock under ESPP Vesting of restricted shares
From March 31, 2023 to June 30, 2023 Exercise of vested options, net of issuance costs of $0.3 million Vesting of restricted shares
From December 31, 2022 to March 31, 2023 Purchase of common stock under ESPP Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.2 million
From December 31, 2021 to December 31, 2022 Issuance of common shares Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.9 million Purchase of common stock under ESPP
From June 30, 2022 to September 30, 2022 Issuance of common shares Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.3 million Purchase of common stock under ESPP
From March 31, 2022 to June 30, 2022 Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.2 million
From December 31, 2021 to March 31, 2022 Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.2 million Purchase of common stock under ESPP
From December 31, 2020 to December 31, 2021 Issuance of common shares, net of issuance costs of $5.4 million Vesting of restricted shares Exercise of vested options, net of issuance costs of $2.6 million Purchase of common stock under ESPP
From June 30, 2021 to September 30, 2021 Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.4 million Purchase of common stock under ESPP
From March 31, 2021 to June 30, 2021 Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.4 million
from December 31, 2020 to March 31, 2021 Issuance of common shares, net of issuance costs of $5.4 million Vesting of restricted shares Exercise of vested options, net of issuance costs of $1.5 million Purchase of common stock under ESPP
From December 31, 2019 to December 31, 2020 Issuance of common shares, net of issuance costs of $46.4 million Vesting of restricted shares Exercise of vested options, net of issuance costs of $1.2 million Purchase of common stock under ESPP Issuance of common stock for license agreements
From June 30, 2020 to September 30, 2020 Issuance of common shares,net of issuance costs of $32.8 million Vesting of restricted shares Exercise of vested options Purchase of common stock under ESPP
1.Common shares offered by the company 6,428,572 shares 2.The number of common shares to be outstanding after the offering is based on 61,960,804 common shares outstanding as of June 15, 2020
From March 31, 2020 to June 30, 2020 Issuance of common shares, net of issuance costs of $3.1 million Vesting of restricted shares Exercise of vested options
From December 31, 2019 to March 31, 2020 Vesting of restricted shares Exercise of vested options Issuance of common shares related to license agreement
from December 31, 2018 to December 31, 2019 Issuance of common shares, net of issuance costs of $25.1 million Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.3 million
from June 30, 2019 to September 30, 2019 Issuance of common shares, net of issuance costs of $2.3 million Vesting of restricted shares Exercise of vested options
from March 31, 2019 to June 30,2019 Issuance of common shares, net of issuance costs of $1.3 million Vesting of restricted shares Exercise of vested options
from December 31, 2018 to March 31, 2019 Issuance of common stock, net of issuance costs of $1.2 million Vesting of restricted shares Exercise of vested options
from December 31, 2017 to December 31, 2018 Issuance of common stock, net of issuance costs of $23.8 million Vesting of restricted shares Exercise of vested options, net of issuance costs of $0.4 million Repurchase of treasury shares Issuance of shares to ViaCyte
from December 31, 2016 to December 31, 2017 Vesting of restricted shares Exercise of vested options
from December 31, 2015 to December 31, 2016 Conversion of Convertible Loans Receipt of Series A-3 Subscription Receivable Issuance of Series B Preferred Shares, net of issuance costs of $1.8 million Conversion of redeemable convertible preferred shares into common share Adjustment to Noncontrolling interest upon share exchange for TRACR Issuance of common stock, net of issuance costs of $8.3 million Repurchase of treasury shares Vesting of restricted shares Exercise of vested options
The conversion of all 27,135,884 of our outstanding preferred shares into common shares on a one-for-one basis immediately prior to the closing of this offering; The issuance of 328,017 common shares to Dr. Emmanuelle Charpentier immediately prior to the closing of this offering pursuant to a call option agreement, dated March 20, 2015, between us and Dr. Emmanuelle Charpentier, or the Call Option Agreement; The filing and effectiveness of our amended articles of association and creation of authorized and conditional share capital of 31,724,612 common shares upon closing of this offering; The issuance and sale by us in the concurrent private placement of 2,500,000 common shares to Bayer BV; No exercise of the underwriters’ over-allotment option to purchase up to 600,000 additional common shares.
from December 31, 2015 to June 30, 2016 Repurchase of treasury shares Vesting of restricted shares Conversion of convertible loans into Series B preferred shares at $13.43 per share (unaudited) Receipt of Series A-3 Subscription Receivable Issuance of Series B Preferred Shares, net of issuance costs of $1.8 million
同花顺个股页面 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。

【免责声明】本产品中的行情数据及资讯信息来源于第三方，长江证券不对收集数据的版权、真实性、准确性及传输过程中发生的传送错误承担法律责任。本内容仅供参考，不作为投资决策依据，长江证券不对因据此操作产生的盈亏承担任何责任。投资有风险，入市需谨慎。